Prothena Corporation PLC (PRTA)

NASDAQ: PRTA · IEX Real-Time Price · USD
33.01
-0.10 (-0.30%)
Aug 8, 2022 4:00 PM EDT - Market closed
-0.30%
Market Cap 1.55B
Revenue (ttm) 201.57M
Net Income (ttm) 67.42M
Shares Out 46.81M
EPS (ttm) 1.55
PE Ratio 21.30
Forward PE 64.10
Dividend n/a
Ex-Dividend Date n/a
Volume 278,177
Open 33.17
Previous Close 33.11
Day's Range 32.52 - 33.82
52-Week Range 21.06 - 79.75
Beta 1.31
Analysts Buy
Price Target 68.21 (+106.6%)
Earnings Date Aug 8, 2022

About PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and P... [Read more...]

Industry Biotechnology
Founded 2012
CEO Gene Kinney
Employees 82
Stock Exchange NASDAQ
Ticker Symbol PRTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is 68.21, which is an increase of 106.63% from the latest price.

Price Target
$68.21
(106.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Prothena to Report Second Quarter 2022 Financial Results on August 8th

DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pro...

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built ...

Prothena to Participate in Jefferies Healthcare Conference

DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pro...

Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.

Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock

RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the ...

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investiga...

DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on p...

Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

Prothena (PRTA) IND Application Gets FDA Clearance for AD

Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for...

DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dy...

Prothena to Participate in Stifel 2022 Virtual CNS Days

DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pr...

Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD/PD 2022

DUBLIN, Ireland, March 16, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pr...

Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Hi...

DUBLIN, Ireland, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pro...

Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 1...

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pro...

Will Prothena (PRTA) Report Negative Q4 Earnings? What You Should Know

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nikola signs multiyear deal for Proterra battery technology

Nikola Corp. has signed a multiyear deal with battery maker Proterra Inc. to use Proterra battery packs in its electric trucks. It is the first Class 8 truck maker to align with Proterra Powered, a newe...

Other symbols: NKLA

5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary ...

Other symbols: BNTXDVAXMRNANTLA

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared f...

7 A-Rated Biotechs to Buy for the Long Run

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Prothena to Participate in JMP Securities Hematology and Oncology Summit

DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on pro...

Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus

Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.

7 A-Rated Healthcare Stocks to Buy for the Long Haul

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared...